Characteristics of the 170 patients with SLE
| Characteristics | Patients (n=170) |
|---|---|
| Age [mean±SD] (year) | 40 [11] |
| Gender, female (n, %) | 148 (87) |
| Ethnicity | |
| Caucasian (n, %) | 122 (71.8) |
| African-American (n, %) | 28 (16.4) |
| Asian (n, %) | 18 (10.6) |
| Others (n, %) | 2 (1.2) |
| Mean BMI [±SD] | 25 [5] |
| Current smokers (n, %) | 41 (24) |
| Median disease duration [range] (year) | 7.9 [0.6–31.0] |
| Photosensitivity (n, %) | 102 (60) |
| Malar rash (n, %) | 80 (47,3) |
| Discoid lupus (n, %) | 20 (11,8) |
| Renal disorder (n, %) | 48 (28) |
| Mean creatinine clearance (mL/min) [±SD] | 108 [34] |
| Low levels of complement (C3) (n, %) | 20 (11.8) |
| Median PGA [range] | 0.11 [0–2.6] |
| Active disease (SELENA-SLEDAI ≥6) (n, %) | 15 (8.8) |
| Median SELENA-SLEDAI score [range] | 1 [0–18] |
| Associated APS (n, %) | 28 (16) |
| Treatment variables | |
| Ever use of prednisone (n, %) | 137 (80) |
| Current prednisone use (n, %) | 94 (55.3) |
| Actual prednisone dosage [mean±SD] (mg/day) | 8.7 [6.2] |
| Ever use of immunosuppressive drugs (n, %) | 69 (40) |
| Current use of immunosuppressive drugs (n, %) | 32 (19) |
| Current anticoagulant treatment (n, %) | 7 (4) |
| Mean blood HCQ concentration at M1 [±SD] (ng/mL) | 1035 [535] |
APS, antiphospholipid syndrome; BMI, body mass index; HCQ, hydroxychloroquine; PGA, physicians’ global assessment; SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index; SLE, systemic lupus erythematosus.